Apellis Pharmaceuticals has stopped development of APL-9 in severe COVID-19 patients after an interim review of phase 1/2 mortality data. The review found adding the C3 therapy to standard of care had no meaningful effect on mortality, prompting Apellis to pull the plug on the program.